- Home
- TVRD
TVRD
Tvardi Therapeutics Inc. Common Stock
as 11-25-2025 3:20pm EST
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SUGAR LAND |
| Market Cap: | 246.5M | IPO Year: | N/A |
| Target Price: | $51.67 | AVG Volume (30 days): | 160.8K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.78 - $43.65 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tvardi Therapeutics Inc. Common Stock News
TVRD Breaking Stock News: Dive into TVRD Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Business Wire
7 days ago
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Associated Press Finance
12 days ago
Tvardi: Q3 Earnings Snapshot
Business Wire
12 days ago
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
Business Wire
21 days ago
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Zacks
a month ago
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
Zacks
a month ago
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
BioPharma Dive
a month ago
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance
Compare TVRD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVRD Tvardi Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.